Eli Lilly and Co. has discontinued a Phase II trial of its investigational Alzheimer's disease drug LY2886721, a beta secretase inhibitor, after cases of abnormal liver tests were identified. Lilly believes the liver problems are not linked to how the drug works, and it still wants to develop beta secretase inhibitors for Alzheimer's.

Full Story:

Related Summaries